Novel lipid metabolism factor HIBCH inhibitor synergizes with doxorubicin to suppress osteosarcoma growth and impacts clinical prognosis in osteosarcoma patients
This study reveals the critical role of lipid metabolism in OS progression and suggests a new therapeutic strategy against chemotherapy resistance in OS based on the synergistic combination of SBF-1 with DOX.
Authors
- Xuhui Yuan
- Bo Yu (ORCID: https://orcid.org/0000-0002-5579-6806)
- Haiqi Ding
- Xinyu Fang (ORCID: https://orcid.org/0000-0001-6337-8009)
- Hongyan Li
- Wenming Zhang (ORCID: https://orcid.org/0000-0002-9575-7713)
- Qijing Wang (ORCID: https://orcid.org/0000-0003-4186-4617)
- Lan Lin (ORCID: https://orcid.org/0000-0003-4778-0887)
Institutions
- Fujian Medical University (CN)
- Jinan University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Journal of bone oncology
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1016/j.jbo.2024.100652
- Citations
- 3
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.70
Funders
- National Natural Science Foundation of China